Theelderlypopulation,oftenburdenedwithmultiplecomorbiditiessuchashypertension,diabetes,andrenalinsufficiency,facesasignificantlyhigherriskofthromboembolicdiseases.Anticoagulanttherapyforthisgroupispar
Anticoagulanttherapyisacornerstoneinmanagingthromboembolicrisksacrossdiverseclinicalscenarios,fromperioperativecaretochronicdiseasemanagement.Amonglowmolecularweightheparins(LMWHs),EnoxaparinSodiumand
Anticoagulanttherapyplaysavitalroleinpreventingandtreatingthromboembolicdiseases,andthedemandforsafe,effective,andpopulation-specificanticoagulantsisincreasinglyprominentinclinicalpractice.Asalowmolec
Asacornerstonelowmolecularweightheparin(LMWH),EnoxaparinSodiumiswidelyrecognizedasthefirst-linetherapyforpreventingandtreatingvenousthromboembolism(VTE),supportingcardiovascularsurgeries,andmanaginghe
Anticoagulanttherapiesstandasacornerstoneinmanagingthromboticdisorders,whichaccountforasignificantportionofglobalcardiovascularmortality.Heparins,includingunfractionatedheparin(UFH)andlowmolecularweig